*********************************
There is now a CONTENT FREEZE for Mercury while we switch to a new platform. It began on Friday, March 10 at 6pm and will end on Wednesday, March 15 at noon. No new content can be created during this time, but all material in the system as of the beginning of the freeze will be migrated to the new platform, including users and groups. Functionally the new site is identical to the old one. webteam@gatech.edu
*********************************
Sydney Ginn
BME Ph.D. Thesis Proposal Presentation
Date: 2021-10-26
Time: 12:00 - 2:00 pm
Location / Meeting Link: https://emory.zoom.us/j/99920242765
Committee Members:
Rebecca D. Levit, MD (Advisor)
Michael A. Burke, MD
J. Brandon Dixon, PhD
Andrés García, PhD MSE
Susan N. Thomas, PhD
Title: The Consequence of Impaired Lymphatic Drainage on Rejection in Cardiac Transplantation
Abstract: The leading cause of chronic cardiac transplant rejection—coronary artery vasculopathy (CAV)—remains a major factor limiting long-term survival in heart transplant patients worldwide. The disease causes concentric intimal thickening along the coronary arteries leading to luminal narrowing and blood flow restriction. CAV pathophysiology is thought to involve chronic inflammation and various immunogenic factors, implicating the lymphatic network as a potential therapeutic target. During heart transplantation, the lymphatic network is severed upon donor heart excision and not surgically reconstructed. The consequence resulting from severed lymphatic vessels in transplanted hearts is unknown. An intact lymphatic network is imperative in maintaining heart health through immune cell trafficking and tissue-fluid homeostasis. Previous studies have shown the beneficial effects of augmenting lymphatic growth via VEGF-C/VEGFR-3 signaling on cardiac function by simultaneously enhancing immune clearance and reducing myocardial edema and fibrosis in a disease model of myocardial infarction. We hypothesize this disruption in lymphatic drainage potentiates inflammation by impeding the egress of immune cells and pro-inflammatory cytokines out of the donor heart exacerbating transplant rejection. Preliminary results in our retrospective clinical study indicate significant differences in lymphatic area at earlier timepoints in an allograft’s lifespan between transplant patients with and without a clear clinical diagnosis of CAV. These data suggest modulating lymphatic development directly after cardiac transplantation may predetermine transplant outcomes by establishing critical routes of drainage earlier in the process. The long-term goal of this study is to elucidate the consequence of lymphatic dysfunction in heart transplant rejection and develop a localized, sustained lymphangiogenic-focused therapy to combat the implications of this disease. In Specific Aim 1, we will identify the effect of severed lymphatics on immune cell infiltration and rejection severity in a heterotopic abdominal heart transplant rodent model. In Specific Aim 2, we will evaluate the effects of localized lymphatic augmentation on donor grafts utilizing a poly(ethylene glycol)-based hydrogel incorporating VEGF-C. Understanding pathologic conditions associated with lymphatic dysfunction in cardiac transplantation will provide novel therapeutic targets that enhance the longevity of donor grafts and reduce mortality among the transplant community.
